Propess,SYNPITAN FORT
Phase 3Small molecule
Propess,SYNPITAN FORT is one of 15 small molecule programs targeting Premature rupture of membranes. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Premature Rupture of Membranes
#DrugCompanyPhaseTrials
1Cytotec
PfizerApproved
Imdur
OOmnivium
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
E-Mycin
AAzurity Pharmaceuticals
Phase 3
Antibiotic
PfizerPhase 3
PGE2
UUnknown Sponsor
Approved
Indocin
LLife Extension Foundation Inc.
Phase 2
Antibiotics Administration
TThe Central and Eastern European Gynecologic Oncology Group
Phase 3
Propess,SYNPITAN FORT
EErzincan Military Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Propess,SYNPITAN FORT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- EErzincan Military Hospital